Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Current Deferred Revenue (2016 - 2026)

Standard Biotools has reported Current Deferred Revenue over the past 16 years, most recently at $38.9 million for Q4 2025.

  • Quarterly Current Deferred Revenue rose 279.1% to $38.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.9 million through Dec 2025, up 279.1% year-over-year, with the annual reading at $38.9 million for FY2025, 279.1% up from the prior year.
  • Current Deferred Revenue was $38.9 million for Q4 2025 at Standard Biotools, down from $42.5 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $48.5 million in Q2 2024 and troughed at $10.3 million in Q4 2024.
  • The 5-year median for Current Deferred Revenue is $17.2 million (2021), against an average of $23.5 million.
  • Year-over-year, Current Deferred Revenue surged 1088.89% in 2021 and then tumbled 73.28% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $17.9 million in 2021, then dropped by 18.45% to $14.6 million in 2022, then dropped by 20.54% to $11.6 million in 2023, then dropped by 11.48% to $10.3 million in 2024, then soared by 279.1% to $38.9 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Current Deferred Revenue are $38.9 million (Q4 2025), $42.5 million (Q3 2025), and $43.0 million (Q2 2025).